About 200 reports

  • By Application (Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Personality Disorder, Attention Deficit Disorder)
  • Description

By Application (Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Personality Disorder, Attention Deficit Disorder) ##. ##. ##.

  • Mental Health
  • World
  • Market Shares
  • PERSONALITY DISORDER
  • BEHAVIORAL REHABILITATION MARKET

It is projected that ##% of adults in the United States suffer from at least one personality disorder.

  • Healthcare
  • United States
  • Company
  • Market Competition
  • Universal Health Services, Inc.
  • brexpiprazole - Drug Profile

It is in Phase II/ III stage of development for the treatment for borderline personality disorder in U. S.

  • Antipsychotic
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • Otsuka Pharmaceutical Co., Ltd.
  • R&D Progress Research and Development Brief
  • Licensing and Collaboration

IT IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT FOR BORDERLINE PERSONALITY DISORDER.

  • Antipsychotic
  • Mental Health
  • Psychotic Disorder
  • Therapy
  • Otsuka Pharmaceutical Co., Ltd.
  • THE MENNINGER CLINIC ACQUIRED WEINBERGER CLINIC
  • MCLEAN HOSPITAL

The details ##.

  • Ambulatory Care
  • Health Services
  • Hospital
  • Psychotic Disorder
  • World
  • RISK FACTORS AND COMORBIDITIES FOR OUD
  • 4.1.1 ETIOLOGY

The most common comorbidities associated with OUD are psychiatric disorders such as major depression, anxiety, and personality disorders.

  • Opioid
  • Therapy
  • United States
  • Forecast
  • Clinical Trial profile. 202 Trial Title
  • Clinical Trial profile. 49 Trial Title

USA) Central Nervous System Psychosis, Schizoaffective Disorder, Schizophrenia, Schizophreniform Disorder (C Reactive Protein (Pentraxin ## or CRP), Carbohydrate Antigen ##-## (CA##-##)) Completed Phase II/ III Interventional Cellavie; ethyl-eicosapentaenoic acid Oslo Un

  • Antipsychotic
  • Clinical Trial
  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • KYOWA KIRIN CO LTD
  • PIPELINE BY GILEAD SCIENCES INC, H1 2020

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • Risk Factors and Comorbidities for OUD
  • 3.2 RISK FACTORS AND COMORBIDITIES

THE MOST COMMON COMORBIDITIES ASSOCIATED WITH OUD ARE PSYCHIATRIC DISORDERS SUCH AS MAJOR DEPRESSION, ANXIETY, AND PERSONALITY DISORDERS.

  • Epidemiology
  • Hospital
  • Opioid
  • Therapy
  • Forecast
  • 3.4.2 Forecast Assumptions and Methods: 12-Month Total Prevalence of PTSD

PTSD, alcohol and drug use disorders, and selected mood, anxiety, and personality disorders were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-##.

  • Anxiety Disorder
  • Epidemiology
  • Mental Health
  • Pathology
  • Forecast
  • Products and services segmentation (2019)
  • Products and services segmentation (2019)

While there is not one factor that is known to cause these disorders, there are numerous measurable factors that can contribute to the development of these diseases. disorders.

  • Addiction Disorder
  • Mental Health
  • Pathology
  • Canada
  • Demand
  • PIPELINE BY KYOWA KIRIN CO LTD, H2 2019
  • PIPELINE BY GILEAD SCIENCES INC, H2 2019

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • Gilead Sciences, Inc.
  • 4.2 CLASSIFICATION OR STAGING SYSTEMS
  • 7.5 CLEARER DIAGNOSTIC GUIDELINES

PTSD, alcohol and drug use disorders, and selected mood, anxiety, and personality disorders were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-##.

  • Anxiety Disorder
  • Mental Health
  • Pathology
  • Pharmaceutical
  • Therapy
  • 21.5.1 Business Overview
  • IT IS MESENCHYMAL STEM CELLS-BASED INJECTION INDICATED FOR THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

IT IS ALSO DEVELOPING OTHER STEM CELL-BASED PRODUCTS IN SUCH AS PNEUMOSTEM (INDICATED FOR BORDERLINE PERSONALITY DISORDER) AND NEUROSTEM (INDICATED FOR Alzheimer' s disease).

  • Biopharmaceutical
  • Gene Therapy
  • Medical Biotechnology
  • Therapy
  • World
  • Hisamitsu Pharmaceutical and Kyowa Hakko Kirin Sign Commercialization Agreement for HP-3000

ONE UNIT REFERS TO ONE SPECIALTY BED.

  • Hospital
  • Mattress
  • Wound Care
  • East Asia
  • Japan
  • ORPEA SA: KEY FACTS
  • 17.7. ORPEA SA

Business Description disorders, eating disorders, borderline personality disorders, age-related psychiatric disorders, and certain psychotic disorders.

  • Health Care Provider
  • Health Services
  • Healthcare
  • Western Europe
  • Market Size
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SANDOZ

Therapy Area Cardiovascular Central Nervous System Dermatology Ear Nose Throat Disorders Gastrointestinal Genetic Disorders Genito Urinary System And Sex Hormones Hormonal Disorders Infectious Disease Musculoskeletal Oncology Respiratory Women' s Health Immunology No. of Deals

  • Biosimilar
  • Healthcare
  • Medical Biotechnology
  • Pharmaceutical
  • Sandoz Inc.
  • Clinical Trial profile. 35 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Mental Health
  • Psychotic Disorder
  • Therapy
  • Pfizer Inc.
  • APR 08, 2019: ORYZON TO PRESENT FIRST IN HUMAN EFFICACY DATA WITH VAFIDEMSTAT AT THE 27TH EUROPEAN CONGRESS OF PSYCHIATRY IN WARSAW
  • AGGRESSION SCORES IN AUTISM: REIMAGINE, THIRD COHORT CLINICAL DATA", AND "VAFIDEMSTAT: THE FIRST EPIGENETIC APPROACH IN ALZHEIMER S DISEASE".

The aggregated results from the ADHD cohort plus the Borderline Personality Disorder (BPD) cohort will also be presented.

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • PARTNERSHIPS

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Dermatological Condition
  • Healthcare
  • Pathology
  • Pharmaceutical
  • LEO Pharma A/S
  • Sep 05, 2019: Evgen Pharma: Agreement for supply of SFX-01 for autism clinical trial
  • Sep 23, 2019: ORYZON presents new data on vafidemstat

Oryzon Genomics Clinical and Product Development vice-president Dr Michael Ropacki said: " The REIMAGINE trial of vafidemstat has now produced positive results in three debilitating psychiatric disorders with high-unmet medical need: ADHD, autism spectrum disorder, and borderli

  • Clinical Trial
  • Hospital
  • Neurological Disorder
  • Neurology
  • Pharmaceutical
  • BREXPIPRAZOLE - DRUG PROFILE

It is in Phase II stage of development for the treatment for borderline personality disorder.

  • Antipsychotic
  • Mental Health
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • BREXPIPRAZOLE - DRUG PROFILE

It is in Phase II stage of development for the treatment for borderline personality disorder.

  • Anxiety Disorder
  • Mental Health
  • Pharmaceutical
  • Therapy
  • Tonix Pharmaceuticals Holding Corp.
  • Description

Chapter ## provides an introduction to the report.

  • Therapy
  • United States
  • Demand
  • Social Conditions
  • Clinical Trial profile. 168 Trial Title
  • 5. All the trials included are unique trials.

## ## ## ## ## ## ## ## China ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Turkey Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are ta

  • Antipsychotic
  • Cardiovascular Drug
  • Clinical Trial
  • Neurology
  • Psychotic Disorder
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Addiction Disorder
  • Antiseptics
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • JIANGSU HENGRUI MEDICINE CO LTD
  • PIPELINE BY IO BIOTECH APS, H1 2020

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Chemotherapy
  • Lung Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Clinical Trial profile. 35 Trial Title
  • Clinical Trial profile. 34 Trial Title

Post-Traumatic Stress Disorder (PTSD) Therapeutics, E## Countries, Clinical Trials by Phase, 2020* CLINICAL TRIALS BY PHASE IN E## COUNTRIES Post-Traumatic Stress Disorder (PTSD) Therapeutics, E## Countries, Clinical Trials by Phase, 2020* Post-Traumatic Stress Disorder (PTSD

  • Anxiety Disorder
  • Clinical Trial
  • Hospital
  • Neurology
  • Therapy
  • 31.6. ORPEA SA

Business Description disorders, eating disorders, borderline personality disorders, age-related psychiatric disorders, and certain psychotic disorders.

  • Health Care Provider
  • Health Services
  • Healthcare
  • Northern Europe
  • Market Size
  • 6 Inborn Gene or Chromosome Alterations- Recent Developments

Among them, the treatment of behavioral alterations present in patients with psychiatric diseases such as Borderline Personality Disorder (BPD), Autistic Spectrum Disorder, Attention Deficit and Hyperactivity Disorder, and others.

  • Clinical Trial
  • Diagnostics
  • Genetic Testing
  • Neurological Disorder
  • Pathology